Key result
Elevated high-sensitive troponin assays were associated with an increased risk of death (HR 2.66; 95% CI 1.31-5.44) and non-fatal AMI (HR 2.14; 95% CI 1.15-3.98) in patients with AMI.
Why the study?
Do high-sensitive troponin assays improve early diagnosis and prognostication of acute myocardial infarction compared to conventional cardiac troponin assays?
Meta-Analysis (n=5,192)
Do high-sensitive troponin assays improve early diagnosis and prognostication of acute myocardial infarction compared to conventional cardiac troponin assays?
High-sensitive troponin assays provide superior early diagnostic sensitivity within 3 hours of symptom onset and significant prognostic value for death and non-fatal AMI compared to conventional assays.
May guide post-AMI risk stratification and follow-up intensity; extends meta-analytic support for hs-troponin prognostication.
BACKGROUND/AIM: To determine the diagnostic and prognostic utility of high-sensitive troponin assays in the very early phase of acute myocardial infarction (AMI) (less than 3 h since symptoms onset) by performing a meta-analysis of prospective studies. METHODS: Relevant studies were identified by searches of MEDLINE and Elsevier Sciencedirect until 31 January 2014 and by reviewing the reference lists from retrieved articles. Prospective studies that reported diagnostic utility in AMI using both high-sensitive troponin assays and conventional cardiac troponin, and reported the estimates of hazard ratio (HR) with 95% confidence intervals (CI) for prognostic utility were included. Data were extracted independently by two authors and summary estimates of association were obtained using a random effects model. RESULTS: Of the seven studies included, four studies reported the diagnostic utility of high-sensitive troponin assays (2863 patients) and three reported the prognostic utility in AMI (2329 patients). Within 12 h of symptoms onset, the pooled sensitivity and specificity of high-sensitive troponin assays were 0.89 (95% CI 0.85-0.91) and 0.89 (95% CI 0.85-0.92), respectively, and within 3 h, the pooled sensitivity and specificity of high-sensitive troponin assays were 0.79 (95% CI 0.71-0.85) and 0.92 (95% CI 0.88-0.96) respectively. Compared with conventional cardiac troponin assays, the high-sensitive troponin assays had higher sensitivity (0.89 vs 0.72) but lower specificity (0.89 vs 0.95) in diagnosing AMI within 12 h of symptoms onset. Within 3 h, the sensitivity of high-sensitive troponin assays was still higher (0.79 vs 0.59), but the specificity was almost the same (0.92 vs 0.95) as that of conventional troponin assays. The elevated high-sensitive troponin assays had an overall pooled HR of 2.66 (95% CI 1.31-5.44) and 2.14 (95% CI 1.15-3.98) for the end-points of death and non-fatal AMI respectively. CONCLUSIONS: These findings provide quantitative data supporting high-sensitive troponin assays having early diagnostic and prognostic utility in AMI.
No takes yet. Share an insight, caveat, or question.
Li et al. (2014) conducted a meta-analysis in Acute myocardial infarction (n=5,192). High-sensitive troponin assays vs. Conventional cardiac troponin assays was evaluated on Death (HR 2.66, 95% CI 1.31-5.44). Elevated high-sensitive troponin assays were associated with an increased risk of death (HR 2.66; 95% CI 1.31-5.44) and non-fatal AMI (HR 2.14; 95% CI 1.15-3.98) in patients with AMI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: